Active filters
Category
-
Antibodies
- Primary Antibodies
Antibody Hosts
- Human
Filter by
Target Symbol
- S (15)
- CD274 (11)
- N (6)
- FITC (5)
- GLB1 (5)
- EGFR (4)
- TNF (3)
- CD80 (2)
- FN1 (2)
- IL2RA (2)
- S PROTEIN (2)
- SARS-COV-2 N PROTEIN (2)
- ALPHA-GAL EPITOPE (1)
- BETVI (1)
- BRD4 (1)
- CBX1 (1)
- CBX2 (1)
- CBX5 (1)
- CD22 (1)
- CD33 (1)
- CD38 (1)
- CD4 (1)
- CD40 (1)
- CD40LG (1)
- CD52 (1)
- CD70 (1)
- CEA (1)
- DESMOSOME/HEMIDESMOSOME (1)
- EPHA2 (1)
- ERBB2 (1)
- F (1)
- FAS (1)
- FCGR1A (1)
- FOXP1 (1)
- FOXP2 (1)
- FOXP4 (1)
- GM2 (1)
- IL6R (1)
- ITGA2B (1)
- ITGA4 (1)
- ITGA5 (1)
- ITGAL (1)
- KMT5C (1)
- L3MBTL1 (1)
- MS4A1 (1)
- PHLPI (1)
- PRDM4 (1)
- PRDM9 (1)
- PRMT3 (1)
- PRMT5 (1)
- RHD (1)
- SARS-COV-2 SPIKE PROTEIN (1)
- SETD7 (1)
- SFMBT1 (1)
- SSB (1)
- TDRD3 (1)
- TNFSF4 (1)
- TOP1 (1)
- TRIM21 (1)
- TYRP1 (1)
- VEGFA (1)
- WDR5 (1)
Reactivities
Applications
Isotypes
Clonalities
Conjugates
Modifications
- This is a chimeric antibody created as part of a panel offering antibodies of the same specificity in different formats (species, isotype, subtype and modified versions) for use as isotype controls. (14)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. (13)
- This chimeric human antibody was made using the variable domain sequences of the original VHH format, for improved compatibility with existing reagents, assays and techniques. (12)
- This reformatted human antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (6)
- This full-length, reformatted human antibody was made using the variable domain sequences of the original Human scFv format, for improved compatibility with existing reagents, assays and techniques. (4)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques. (2)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This reformatted human antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric human antibody was made using the variable domain sequences of the original IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric human antibody was made using the variable domain sequences of the original Mouse IgM format, for improved compatibility with existing reagents, assays and techniques. (1)
- This is a chimeric human antibody, based on the original mouse IgG2a format, created for improved compatibility with existing reagents, assays and techniques. (1)
- This is a reformatted human IgG1 antibody based on the therapeutic Fab fragment. NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. (1)